Alzheimer s disease (AD) is currently the most common form of dementia worldwide. The synaptic loss at the neurotransmitter system level and the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles are major events that identify AD among other dementias, at the cellular level. From a chemical point of view, it is well-known that A(beta) peptide coordinates physiological metals, such as Cu and Zn, which, in AD patients brain, are poorly distributed and concentrated in amyloid plaques. Despite the fact that aggregation of the A(beta) peptide is one of the most important features of AD pathogenesis, the function of the extracellular plaques composed by this peptide is not fully understood. The hypothesis that A(beta) neurotoxicity is best explained by its oligomeric form is well accepted. There are evidences supporting the link between physiological metals and oligomerization of A(beta). Metal-Protein Attenuating Compounds (MPACs), a promising class of compounds for the management of AD and differ from strong chelating agents, once, instead of systematically removing metals, they correct abnormal interactions with A(beta), inhibiting the A(beta) oligomerization, as well as preventing redox reactions that can ultimately generate harmful reactive oxygen species (ROS). In this context, the present work evaluates four compounds with potential to act as MPACs, namely, INHHQ, HPCIH, H2QBS and INHOVA. Among them, three substances (INHHQ, HPCIH and INHOVA) belong to the chemical class of aroylhydrazones. The stability of each compound was tested over 30 h in water/DMSO mixtures of different concentrations in order to define the best condition for the biological studies and a suitable stability pattern was observed for all compounds, with the exception of INHOVA, which showed high sensibility to hydrolysis. INHHQ, HPCIH and H2QBS were analyzed in vitro in order to evaluate their ability to compete with A(beta) for Cu and Zn, by (1)H and (1)H x (15)N HSQC NMR analyses: a similar metalsequestering profile for INHHQ and HPCIH was observed, H2QBS, on the other hand, showed a higher capacity for the removal of metal ions from A(beta). Cell studies were performed in order to assess cytotoxicity. INHHQ and HPCIH showed the most promising profiles, suggesting that their toxicity was related to the amyloid precursor protein (APP) overexpression. Both substances were then evaluated concerning their capacity to affect the APP pathway by means of proteomic analyses in an exposed APP-overexpressing cell line. Results suggest possible interaction of both compounds with γ-secretases. In vivo acute toxicity assays were performed, showing no lethality at doses up to 200 mg kg(-1). Several biochemical parameters, such as GSH and Fe, Cu and Zn concentrations in brain, liver, heart and kidneys were evaluated. The results suggested that H2QBS present high capacity to displace biometals in rats, when high doses are administered. In vivo effectiveness studies were performed in order to evaluate the capacity of the most promising substance, i.e., INHHQ, of affecting behavior in animal models. For this purpose, anxiety and memory were evaluated in mice, through Elevated Plus Maze, Open Field and Novel Object Recognition tests. The results indicated that INHHQ treatment does not alter the fear / anxiety-related defensive responses and that doses of 10 mg kg(-1) or higher induce temporary cognitive impairment in healthy mice. Finally, it was proved that an innocuous INHHQ dosage of 1 mg kg (-1) does prevent short- and long-term memory impairment induced by A(beta) oligomers infusion in mice. The findings reported in this thesis definitively point to INHHQ as a good candidate for further pre-clinical trials, as a potential MPAC for AD treatment.